FY2023 Earnings Estimate for Establishment Labs Holdings Inc (NASDAQ:ESTA) Issued By Jefferies Financial Group

Establishment Labs Holdings Inc (NASDAQ:ESTA) – Equities researchers at Jefferies Financial Group increased their FY2023 earnings per share estimates for shares of Establishment Labs in a research report issued on Tuesday, August 13th. Jefferies Financial Group analyst R. Denhoy now anticipates that the company will post earnings per share of $0.28 for the year, up from their prior estimate of $0.26.

Several other brokerages have also recently issued reports on ESTA. BTIG Research restated a “buy” rating and issued a $40.00 target price on shares of Establishment Labs in a report on Thursday, May 16th. ValuEngine upgraded shares of Establishment Labs from a “hold” rating to a “buy” rating in a report on Monday, July 29th. Wells Fargo & Co set a $29.00 target price on shares of Establishment Labs and gave the stock a “buy” rating in a report on Friday, July 12th. Finally, Stephens assumed coverage on shares of Establishment Labs in a report on Thursday, June 6th. They issued an “overweight” rating and a $37.00 target price on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $35.33.

Shares of ESTA stock opened at $21.75 on Thursday. Establishment Labs has a 12-month low of $20.05 and a 12-month high of $30.70. The company has a current ratio of 5.54, a quick ratio of 4.10 and a debt-to-equity ratio of 0.38. The firm’s 50 day moving average is $22.91 and its 200 day moving average is $24.43. The stock has a market capitalization of $472.47 million and a P/E ratio of -19.42.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.08. Establishment Labs had a negative net margin of 37.74% and a negative return on equity of 68.22%. The company had revenue of $21.68 million for the quarter, compared to analysts’ expectations of $20.10 million.

In related news, major shareholder Jw Asset Management, Llc bought 2,500 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were bought at an average price of $25.58 per share, for a total transaction of $63,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 7,000 shares of company stock worth $168,365 in the last 90 days. 2.64% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BBR Partners LLC bought a new position in Establishment Labs in the second quarter worth approximately $445,000. Vanguard Group Inc. bought a new position in Establishment Labs in the second quarter worth approximately $349,000. Tower Research Capital LLC TRC raised its position in Establishment Labs by 257.1% in the second quarter. Tower Research Capital LLC TRC now owns 1,350 shares of the company’s stock worth $30,000 after acquiring an additional 972 shares during the period. JW Asset Management LLC raised its position in Establishment Labs by 1,840.3% in the second quarter. JW Asset Management LLC now owns 3,104,485 shares of the company’s stock worth $68,268,000 after acquiring an additional 2,944,485 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Establishment Labs by 96.3% in the second quarter. JPMorgan Chase & Co. now owns 13,014 shares of the company’s stock worth $273,000 after acquiring an additional 6,386 shares during the period. Institutional investors and hedge funds own 25.86% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Recommended Story: Why do companies issue convertible shares?

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.